Breast Cancer

Cancer, CV Risks Examined for Vaginal Estrogen Tx in Postmenopausal Women

By August 16, 2017

The data showed women with an intact uterus did not have a significantly different risk of stroke, invasive breast cancer, colorectal cancer, endometrial cancer, and pulmonary embolism/deep vein thrombosis (PE/DVT) between those who used vaginal estrogen and those who did not.

Gene Variation May Affect Pharmacokinetics of Breast Cancer Treatment

August 03, 2017

"Our data suggest that the OATP1B1 c.521T>C SNP may influence exemestane pharmacokinetics in humans," the authors write.

Nerlynx Available for Extended Adjuvant Tx of HER2+ Early Stage Breast Cancer

By August 01, 2017

The approval was supported by data from the Phase 3 multicenter, randomized, double-blind, placebo-controlled ExteNET trial (n=2,840) following adjuvant treatment with trastuzumab.

Long-Term Recurrence Assessed in Nipple-Sparing Mastectomies

July 20, 2017

At a median follow-up of 51 months, cancer recurrence developed in 17 patients. None of the recurrences involved nipples retained during mastectomies, the researchers found.

Nerlynx Approved to Reduce Risk of Breast Cancer Recurrence

By July 18, 2017

The invasive disease-free survival was reportedly 94.2% in Nerlynx-treated patients vs. 91.9% in placebo patients after 2 years (hazard ratio [HR] 0.66, 95% CI: 0.49, 0.90; P=0.008).

FDA Committee in Favor of Herceptin Biosimilar Approval

By July 14, 2017

Herceptin, a human epidermal growth factor receptor (HER2) inhibitor, is currently approved to treat HER2-overexpressing metastatic breast cancer as a single agent in patients who have received one or more chemotherapy regimens; or in combination with paclitaxel in patients who have not received chemotherapy.

Advanced Breast Cancer Drug Granted Priority Review

By July 10, 2017

The NDA included data from two trials, MONARCH 1 and MONARCH 2, which are a part of the comprehensive MONARCH clinical trial program.

Cooling Cap FDA-Cleared to Reduce Chemotherapy-Associated Hair Loss

By July 05, 2017

A study of 122 women with Stage I and Stage II breast cancer undergoing chemotherapy particularly associated with hair loss. The study showed that over 66% of patients using DigniCap reported losing less than half their hair.

Study Addresses CA Risks For <i>BRCA1/2</i> Mutation Carriers

June 21, 2017

The researchers found that the increase in breast cancer risk rose quickly in early adulthood and then plateaued, typically for the rest of a woman's life.

Genetics Should Play a Bigger Role in Clinical Decision-Making

June 21, 2017

As home genetic testing grows, patients will be bringing their results to physicians for reaction and response. Physicians will need to be proactively prepared.

Adjuvant Capecitabine Beneficial for Certain Breast Cancer Patients

June 01, 2017

Capecitabine cut risk of relapse, death by 30 percent over five years, researchers say

Text Messaging App Helps Monitor Endocrine Tx Adherence, Side Effects

May 31, 2017

Most patients with breast cancer taking endocrine therapy report intervention helpful in taking drugs

AICR: Diet, Lifestyle Has Significant Impact on Breast CA Risk

May 24, 2017

Overall, women with the highest amounts of daily activity were 13% less likely to develop postmenopausal breast cancer, versus women with the lowest activity levels.

Study Examines ACA Impact on Early Cancer Detection

May 19, 2017

For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.

Prevalence of Metastatic Breast Cancer Assessed in U.S.

May 18, 2017

The researchers estimate that 154,794 U.S. women are living with metastatic breast cancer, up from 105,354 in 1990.

Martial Art May Improve Insomnia, Depression in Breast CA Survivors

May 15, 2017

Researchers asked 90 breast cancer survivors with insomnia and symptoms of depression and daytime sleepiness to undergo weekly cognitive behavioral therapy sessions or weekly classes in a Westernized form of tai chi.

Kisqali Femara Co-Pack Approved by FDA

By May 08, 2017

These kinases are activated upon binding to D-cyclins and play a crucial role in signaling pathways which lead to cell cycle progression and cellular proliferation.

FDA Fast Tracks Metastatic Breast Cancer Combo Treatment

By May 08, 2017

The only adverse event that was grade 3 or higher was fatigue with 16.3% incidence in the treatment group and 13.2% in the control group.

Amneal Introduces New Strength of Thiotepa with Tepadina

By April 27, 2017

Tepadina, an alkylating agent, is indicated to reduce the risk of graft rejection when used with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.

Does Depression Before Breast CA Diagnosis Affect All-Cause Mortality?

April 13, 2017

Newly-developed depression at year 3 was significantly associated with both all-cause mortality and breast cancer-specific mortality among women with late-stage breast cancer.

pH-Balanced Vaginal Gel Assessed for Dyspareunia in Breast CA Survivors

April 10, 2017

The researchers found that both groups experienced a significant improvement of dyspareunia, with no difference between the groups.

Air Pollution Exposure and Breast Cancer: Is There A Link?

April 10, 2017

The researchers found that women with heterogeneously dense versus scattered fibroglandular breasts were more likely to have higher exposure to fine particle matter.

Environmental Toxins Linked to Multiple Diseases, Early Puberty

By April 07, 2017

These studies identified links to increased risks of thyroid, testicular and breast cancer, nonalcoholic fatty liver disease and even the early onset of puberty for boys, which can lead to diseases in adulthood.

Childhood Survivors May be Predisposed to Cancer Later in Life

April 05, 2017

More than one-quarter of patients who survived childhood cancer had developed another cancer by the age of 45.

Aspirin Use Linked to Reduced Risk of Cancer Death

April 04, 2017

The researchers found that regular aspirin use correlated with reduced risk of total mortality compared with nonregular use (multivariable-adjusted relative risks [RRs], 0.93 and 0.89 for women and men, respectively).

Survival Data for Atezolizumab in Triple-Negative Breast Cancer

April 04, 2017

Overall, the response rate to the drug was low - just 11 of 112 patients - however, results were significant for the minority of patients who did respond.

FDA Expands Breast Cancer Indication for Ibrance

By March 31, 2017

The updated approval was based on data from the PALOMA-2 trial, which demonstrated that Ibrance + letrozole significantly extended progression-free survival vs. letrozole + placebo.

Vit D Levels May Correlate With Overall Survival in Breast CA

By March 24, 2017

The researchers found that the overall survival was strongest among premenopausal women in the highest 25OHD tertile group.

Are Antiemetic Prophylactics Being Overprescribed for Chemotherapy?

By March 24, 2017

Study authors identified a total of 8,545 patients undergoing 73,577 administrations of chemotherapy with minimal or low emetic risk.

FDA Approves Breast Cancer Drug Kisqali

By March 14, 2017

The approval was based on results from the Phase 3 MONALEESA-2 clinical trial which included 668 patients randomized to receive either ribociclib plus letrozole (n=334) or placebo plus letrozole (n=334).